glp3.wiki
Approval status varies by treatment

Editorially reviewed · Last updated September 8, 2026 · How we review

Retatrutide vs Orforglipron: Injectable Triple Agonist vs Oral GLP-1

Part of Weight Loss Drug Comparison Index.

Retatrutide vs Orforglipron: Injectable Triple Agonist vs Oral GLP-1

Orforglipron is FDA-approved as Foundayo; retatrutide remains investigational. Both are made by Eli Lilly. Foundayo is a once-daily oral GLP-1 receptor agonist that can be taken with or without food. Retatrutide is a once-weekly injectable triple agonist targeting GLP-1, GIP and glucagon receptors. FDA Foundayo approval, April 1, 2026.

The relevant comparison is an approved oral option versus an investigational injection. Their weight-loss results come from different trials; they do not establish a head-to-head efficacy or tolerability advantage.

Side-by-Side Comparison

RetatrutideOrforglipron
DeliveryOnce-weekly injectionOnce-daily oral pill
Molecule typePeptide (injectable)Small molecule, non-peptide (oral)
ReceptorsGLP-1 + GIP + Glucagon (triple agonist)GLP-1 only (single agonist)
Selected trial weight loss-28.7% at 68 weeks (TRIUMPH-4)-12.4% at 72 weeks (ATTAIN-1)
Dose context12 mg weekly in the selected trial (investigational)36 mg in the older trial formulation; marketed Foundayo has different strengths
Food restrictionsNoneNone (unlike oral semaglutide/Rybelsus)
FDA statusNot approved; Lilly plans a Q1 2027 filingFoundayo approved April 1, 2026
Discontinuation due to any AE12.2-18.2% (TRIUMPH-4)5.3-10.3% (ATTAIN-1)
Safety considerationsGI events and dysesthesia in trialsGI events and additional warnings in the approved label

How the Mechanisms Differ

Orforglipron: One Receptor, Oral Delivery

Orforglipron (LY3502970) is a non-peptide, small-molecule GLP-1 receptor agonist. Unlike injectable GLP-1 drugs (which are peptides that would be destroyed by stomach acid), orforglipron is a small molecule that acts as an allosteric agonist — it binds within a transmembrane pocket on the GLP-1 receptor, distinct from where the natural GLP-1 hormone binds, and stabilizes an active receptor conformation.

Because it is a small molecule, orforglipron is:

  • Chemically stable in stomach acid — no special coating or absorption enhancers needed
  • Resistant to digestive enzymes (DPP-4 and proteases) that would destroy peptide drugs
  • Taken any time of day without fasting or food/water restrictions

This is a significant advantage over oral semaglutide (Rybelsus), which requires 30 minutes of fasting with minimal water.

Retatrutide: Three Receptors, Maximum Efficacy

Retatrutide activates GLP-1, GIP and glucagon receptors. Preclinical research supports effects on energy expenditure and liver fat metabolism, but its human trials do not isolate each receptor's contribution or prove that receptor count determines efficacy. Retatrutide liver-fat trial.
For details on each receptor, see What Is Retatrutide (GLP-3)?.

Weight Loss Comparison

Swipe sideways to see every column.

DrugTrialDurationMax Weight Loss
Retatrutide 12 mgTRIUMPH-4 (Phase 3)68 weeks-28.7%
Orforglipron 36 mgATTAIN-1 (Phase 3)72 weeks-12.4%
Orforglipron 36 mg (T2D)ATTAIN-2 (Phase 3)72 weeks-10.5%
These selected trial results use efficacy estimands, which estimate effects while treatment is taken as specified. TRIUMPH-4 enrolled adults with obesity and knee osteoarthritis, while ATTAIN-1 enrolled adults with obesity or overweight without diabetes. They are not a direct comparison. The 36 mg orforglipron figure refers to the investigational formulation used in those trials, not the marketed tablet strength. The current Foundayo label lists a maximum daily dosage of 17.2 mg; use its approved instructions rather than a trial-dose table. Foundayo label, sections 2.1, 6.1 and 14.

Weight Loss Thresholds (Orforglipron, ATTAIN-1)

ThresholdOrforglipron 36 mgPlacebo
Lost at least 10%59.6%—
Lost at least 15%39.6%—

Switching Between the Two

Lilly's ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable incretins (semaglutide or tirzepatide) to oral orforglipron maintained most of their prior weight loss. Average differences were only 0.9 kg from semaglutide and 5.0 kg from tirzepatide over 52 weeks. This suggests orforglipron could serve as a maintenance option after achieving weight loss on injectable drugs — though switching from retatrutide to orforglipron has not been studied.

Side Effects and Tolerability

RetatrutideOrforglipron
Most commonNausea, diarrhea, constipation, vomitingDiarrhea, nausea, constipation, vomiting, dyspepsia
SeverityMostly mild-moderateMostly mild-moderate
Discontinuation (AEs)12-18%5.3-10.3% (vs 2.7% placebo)
Safety considerationsDysesthesia (tingling/burning) in TRIUMPH-4Approved label includes pancreatitis and gallbladder warnings
The discontinuation figures come from separate trials and cannot establish which drug an individual will tolerate better. Foundayo is not free of serious risks: its current prescribing information includes warnings for acute pancreatitis, severe gastrointestinal reactions, gallbladder disease and diabetic retinopathy complications. It also has drug interactions that a prescriber should review. Foundayo label, sections 5 and 7.

FDA Timeline

MilestoneOrforglipronRetatrutide
U.S. applicationReviewed and approvedBLA planned for Q1 2027
FDA reviewApproved under the National Priority Voucher programNot yet approved
Approval dateApril 1, 2026Not established
Current statusApproved for weight management in eligible adultsPhase 3 diabetes and obesity results reported; still investigational
The FDA approved Foundayo on April 1, 2026. Lilly's latest retatrutide announcement plans a Q1 2027 Biologics License Application, which is not a promised approval or launch date. FDA approval, Lilly retatrutide status.

Lilly's Portfolio Strategy

Eli Lilly is developing both drugs because they serve different patient needs:

  • Orforglipron — for patients who prefer or need oral therapy, needle-phobic patients, maintenance therapy after initial injectable weight loss, or patients who need moderate weight loss (~12%)
  • Retatrutide — for patients seeking maximum weight loss, those with comorbidities like fatty liver disease or knee osteoarthritis where the glucagon mechanism adds specific benefit

An oral option and a weekly injection may suit different preferences, but retatrutide's eventual approved uses and role in treatment have not been established. Trial results do not justify choosing or combining medicines without a clinician's assessment.

Frequently Asked Questions

Is retatrutide better than orforglipron?

No head-to-head trial has established that retatrutide is better. Foundayo (orforglipron) is an approved oral weight-management treatment; retatrutide is investigational. Separate-trial averages, including TRIUMPH-4 and ATTAIN-1, cannot determine which medicine would work best for an individual.

Why does orforglipron produce less weight loss?

The reported averages come from different populations, protocols and durations. Retatrutide has additional GIP and glucagon receptor activity, but these trials do not establish that receptor count explains the numerical difference or predicts individual weight loss.

Can I take orforglipron as a pill while waiting for retatrutide?

Foundayo is now approved for eligible adults. A clinician can assess whether it fits your health needs and other medicines. Evidence about switching from semaglutide or tirzepatide does not establish a switching regimen involving retatrutide. The Foundayo label does not recommend using it with another GLP-1 receptor agonist.

Will Lilly make a retatrutide pill?

There is no announced plan for an oral retatrutide. Retatrutide is a peptide that requires injection. Developing an oral version would face significant technical challenges due to its large molecular size and triple receptor binding requirements. See Retatrutide Pill vs Injection.

Sources

  • U.S. Food and Drug Administration. (2026). Foundayo approval. April 1 announcement.
  • U.S. Food and Drug Administration. (2026). Foundayo prescribing information, revised July 2026. Label.
  • Eli Lilly. (2026). Retatrutide Phase 3 results and planned BLA submission. Release.
  • Eli Lilly. (2025). ATTAIN-1 Phase 3 results. Press release.
  • Wharton, S., et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM. DOI: 10.1056/NEJMoa2511774
  • Eli Lilly. (2025). ATTAIN-MAINTAIN results. Press release.
  • Eli Lilly. (2025). TRIUMPH-4 results. Press release.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Foundayo (orforglipron) is an FDA-approved prescription tablet. Retatrutide remains investigational and has no approved prescribing label.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all compare topics →